Jones Paton Promoted to Lead Life Science Organization After Broad Search 

Continue Reading

miRagen Named Company of the Year, Inscripta Honored as Rising Star
 

Continue Reading

Federal 

Continue Reading

This week, the October Focus newsletter was published for a more detailed look at policy, and other issues, please read Jennifer’s monthly policy update.  

Last week President Trump signed two bills (Patient Right to Know Drug Prices Act and Know the Lowest Price Act) into law that ban gag clauses that were called for in the American Patients First blueprint back in May. These clauses can be included in contracts insurers have with pharmacies — preventing pharmacies from telling customers they can save money on a drug if they pay with cash instead of using their health insurance. These bills are similar to HB18-1284 which was signed into law this past legislative session in Colorado by Governor Hickenlooper.

CBSA continues to be supportive of HB18-1284 as we see it as a way to provide direct out of pocket cost savings for patients in need. At CBSA we are dedicated to patients, ensuring people live longer, healthier lives. We see this as a way to ensure patients receive the needed treatments and cures. We work every day to create an innovation-friendly business environment ensuring that as an industry we deliver value to patient.

To learn more about CBSA’s support of HB18-1284 click here and to learn more about what is happening at the federal level click here.

ArcherDX, MiRagen, Biodesix Named Finalists for Company of the Year Award; Double Helix, Impressio and Inscripta Nominated for Rising Star Award 

Continue Reading

A quick recap of bioscience in recent national and international news.

President Trump recently signed a bill prohibiting pharmacy benefit managers from imposing “gag orders” on pharmacists that prevent them from informing patients when their medications would be cheaper out of pocket.

HHS Secretary Alex Azar has promised more actions on drug pricing in the near future.

You'll find the the full update on Axios.com

The United States-Mexico-Canada Agreement (USMCA)—the updated version of the NAFTA agreement—will promote genetically modified foods.

Rabble.ca has a complete story.

China is targeting medical device makers in the escalating trade war. The most recent round of China’s retaliation puts almost $5 billion on medical technology exports.

Forbes is keeping up with the ongoing developments.

Prima-Temp, a women's healthtech company, has acquired Kindara, another Boulder-based women’s healthtech company.  

Over the last year, in fact, FDA Commissioner Scott Gottlieb has put an emphasis on speeding up the process in getting technology and medications out to the public. This is evidenced by the new Pre- Certification program which would uproot the way software as a medical device is regulated, with the possibility of deeming a company safe instead of focusing on each individual product.